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The catalytic subunits of all class IA phosphoinositide 3-kinases
(PI3Ks) associate with identical p85-related subunits and phos-
phorylate PIP2 yielding PIP3, but they can vary greatly in the
signaling pathways in which they participate. The binding of the
p85 subunit to the p110 catalytic subunits is constitutive, and this
inhibits activity, but some of the inhibitory contacts are reversible
and subject to regulation. Interaction with phosphotyrosine-
containing peptides (RTK-pY) releases a subset of these inhibi-
tory contacts. Hydrogen/deuterium exchange mass spectrometry
(HDX-MS) provides a map of the dynamic interactions unique to
each of the isotypes. RTK-pY binding exposes the p110 helical
domains for all class IA enzymes (due to release of the nSH2
contact) and exposes the C-lobe of the kinase domains of p110b
and p110d (resulting from release of the cSH2 contact). Consistent
with this, our in vitro assays show that all class IA isoforms are
inhibited by the nSH2, but only p110b and p110d are inhibited by
the cSH2. While a C2/iSH2 inhibitory contact exists in all isoforms,
HDX indicates that p110b releases this contact most readily. The
unique dynamic relationships of the different p110 isozymes to the
p85 subunit may facilitate new strategies for speciﬁc inhibitors of
the PI3Ks.
 2012 Elsevier Ltd. Open access under CC BY license. , þ44 1223 402171.
.E. Burke), rlw@mrc-lmb.cam.ac.uk (R.L. Williams).
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The 3-phosphorylated phosphoinositide secondmessengers havewidespread roles in cell signaling.
Their involvement in human diseases such as cancer, diabetes, auto-immunity and inﬂammation has
made the phosphatidylinositol 3-kinases (PI3Ks) that produce these lipid secondmessengers the target
of intense efforts at inhibitor development. In mammals, the PI3Ks consist of eight enzymes (Vadas
et al., 2011). However, all of these enzymes are closely related and have diverged from an ancestral
PI3K known as Vps34, which catalyzes the production of PtdIns(3)P and has been found in all
eukaryotes. Althoughmammalian cells, like other eukaryotes, use PtdIns(3)P in regulating intracellular
sorting, they have evolved the four class I PI3Ks, which produce the second messenger PtdIns(3,4,5)P3.
While this lipid is only a minor constituent of the plasma membrane, its levels can be quickly
modulated by activation of class I PI3Ks and the lipid phosphatase PTEN. The canonical PI3K signaling
pathway starts with receptors that activate the PI3Ks to produce PtdIns(3,4,5)P3 and this lipid in turn
recruits a range of effector proteins with modules, such as PH domains, that have evolved to recognize
this second messenger. The master protein kinase PKB is the best studied and most prominent of these
effectors. Phosphorylation by activated PKB of a series of downstream effectors has a key role in cell
survival, growth, protein synthesis and the cell cycle.
The class IA PI3Ks consist of p110a, p110b and p110d catalytic subunits, which associate tightly with
a p85-related regulatory subunit. The domain organizations (from N- to C-terminus) of the p110
catalytic subunits are identical: adaptor-binding domain (ABD), Ras-binding domain (RBD), C2 domain,
helical domain and kinase domain (Walker et al., 1999; Huang et al., 2007; Berndt et al., 2010; Zhang
et al., 2011). The p85 regulatory subunit consists of a BH domain, an SH3 domain, an N-terminal SH2
domain (nSH2), an iSH2 domain and a C-terminal SH2 domain (cSH2) (Breeze et al., 1996; Liang et al.,
1996; Musacchio et al., 1996; Nolte et al., 1996; Hoedemaeker et al., 1999; Weber et al., 2000). The ABD
binds with high afﬁnity to the iSH2, and this constitutive interaction is essential to stabilize the
catalytic subunit in cells. In addition to this high afﬁnity interaction, the p85 also makes weaker
interactions with the catalytic subunit that greatly down-regulate the basal activity of the catalytic
subunit. The PIK3CA gene encoding the p110a catalytic subunit is one of the most commonly mutated
genes in human tumors (Samuels et al., 2004; Chalhoub and Baker, 2009). The gain-of-function
mutations in the gene are scattered in all domains of PIK3CA (there are only a few mutations in the
RBD, and it is not knownwhether they are gain-of-function). The two most common mutations are in
the helical domain at residue E545 and the C-terminal lobe of the kinase domain at residue H1047.
Simultaneous mutation of these two residues has a synergistic effect in activating p110a, suggesting
that they act independently (Zhao and Vogt, 2008). The wide distribution of the oncogenic mutations
has made it unclear as to the mechanism of up-regulation of PI3K in cancers, however, some of the up-
regulating mutations were shown to increase the afﬁnity of the enzyme for lipid membranes
(Mandelker et al., 2009; Burke et al., 2012; Hon et al., 2012). Several mutations in the p85 regulatory
subunit have also been shown to be oncogenic (Jaiswal et al., 2009; Sun et al., 2010; Urick et al., 2011).
The minimal p85 construct capable of fully down-regulating the basal activity of all three class IA
isozymes (p110a, p110b and p110d) consists of the nSH2, iSH2 and cSH2 domains (Yu et al., 1998; Miled
et al., 2007; Burke et al., 2011; Zhang et al., 2011). SH2 domains are well-characterized modules for
interactingwith phosphotyrosine-containing peptides (Huang et al., 2008), and the SH2 domains of the
p85 subunit facilitate interaction of the class IA PI3Ks with receptor tyrosine kinases and adaptor
proteins that contain tyrosine-phosphorylated YXXM motifs (Carpenter et al., 1993). These pYXXM
motifs interact with the canonical phosphotyrosine peptide-binding site on the SH2 domains, and they
compete with p110 for binding to the SH2 domains. It is common that receptors capable of activating
PI3Ks have two YXXM motifs, and tandem pYXXM motifs lead to much greater activation than single
motifs (Carpenter et al., 1993). Early studies had shown that the nSH2 contacts the helical domain at the
site of the E545, one of the oncogenic hotspot mutations for the p110a catalytic subunit (Miled et al.,
2007). Subsequently, crystallographic analyses of p110/p85 complexes have shown the basic architec-
ture of the inter-subunit interactions,with the p85nSH2 contacting the p110helical domain (Mandelker
et al., 2009) and thep85cSH2contacting thep110kinasedomain (Zhanget al., 2011). It is clear fromthese
studies that the two SH2 domains interact in distinct ways with p110 subunits, yet both domains are
forced to disengage the inhibitory grip on the catalytic subunit in the presence of YXXM-containing
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to a loss of these inhibitory contacts (Miled et al., 2007). The lack of a structure for any full-length p110/
p85 heterodimer hasmade understanding the structural basis for regulation of p110 by p85 challenging,
however, the use of hydrogen deuterium exchange mass spectrometry (HDX-MS) has allowed us to
probe p85 regulation of the class IA holoenzymes.
Hydrogen deuterium exchange mass spectrometry (HDX-MS) has become a powerful method to
determine dynamic structural perturbations in proteins (Engen, 2009). The technique is used to
determine the exchange rate of amide hydrogens with solvent, and this exchange is strongly depen-
dent on the involvement of these amide hydrogens in secondary structure and exposure to solvent. The
time scale of changes in amide protection observed by HDX-MS (seconds to hours) is consistent with
regions that are likely to be involved in slow conformational ﬂuctuations. Recent results using HDX-MS
to examine PI3Ks showed for p110d how interactions with the RTK phosphopeptides increase PI3K
activity by increasing membrane binding (Burke et al., 2011). This study also demonstrated that p110d,
like p110b, interacts with and is inhibited by both the nSH2 and cSH2 domains of p85. The prominent
effect of phosphorylated RTK peptide binding is to cause a release of inhibitory contacts and to facilitate
interaction with lipid membranes (Burke et al., 2011, 2012; Hon et al., 2012). For p110a, oncogenic
mutations throughout the subunit produce changes in exposure that mimic and enhance the dynamic
events that occur in the natural activation mechanism of the wild-type enzyme (Burke et al., 2012).
Previous crystallographic studies have clearly demonstrated the nature of the constitutive interactions
between the p110 subunit and the iSH2 domain of the p85 subunit. In vitro assays have demonstrated
that the class IA enzymes differ in their afﬁnity for substrate and their maximal catalytic rates (Beeton
et al., 2000). We have now examined the dynamics of the p110/p85 interactions for all three class IA
isozymes using HDX-MS and correlated this with enzymatic activity. Our HDX-MS has enabled us to
map dynamic footprints of the p85 subunit on each of the p110 subunits and vice versa. This has
provided insight into the weaker, regulated interactions between the subunits. These results demon-
strate that each of the class IA enzymes has a unique dynamic relationship with the p85 subunit. These
unique responses to the p85 regulatory subunit may partially account for the signaling pathways in
which the members of the class IA PI3Ks function.
Materials and methods
ATPase assays
ATPase assays were carried out using the transcreener ADP2 ﬂuorescence polarization assay
(Bellbrook laboratories). Reactions were performed in 10 mL in 384 well black plates (Corning 3676).
The reactions contained 100 mMATP, and a dilution series of protein concentrations varying from 1 mM
to 1 nM. The proteinwas serially diluted in a buffer containing 50mMHepes pH-7.4, 100mMNaCl, and
2mM TCEP. Experiments were carried out in the presence and absence of a pY phosphopeptide (mouse
PDGFR residues 735–767, with pY740 and pY751 at a ﬁnal concentration of 2 mM, referred to afterward
as pY). Reactions were started by the addition of ATP (ﬁnal concentration 100 mM) in a buffer that gave
a ﬁnal concentration of 50 mMHepes pH-7.4, 100 mMNaCl, 3 mMMgCl2, 1 mM EGTA, and 2 mM TCEP.
Reactions were allowed to run for 60 minwith shaking at 500 rpm. Reactions were stopped using 10 ml
of the transcreener stop buffer (1X Stop & Detect Buffer B, 4 nM ADP Alexa633 Tracer, 109 mg/ml ADP2
antibody). This was allowed to equilibrate for 30 min and then the plate was read using a PHERAStar
plus HTS microplate reader (BMG Labtech), using a ﬂuorescence polarization module with excitation
centered at 633 nm and emission at 650 nm.
Lipid kinase assays
The lipid kinase activity was determined using a modiﬁed membrane capture assay measuring
production of 32P-labeled PIP3 (Knight et al., 2007). Lipid vesicles were used at a ﬁnal concentration of
1mg/mL andwere composed of 5% brain PIP2, 20% brain PS, 45% brain PE,15% brain PC,10% cholesterol,
and 5% sphingomyelin (Avanti Polar Lipids). The lipid solution and RTK-pY (if relevant) was mixed with
each protein construct at a ﬁnal concentration of enzyme in the reaction of 10 nM, with a ﬁnal buffer
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phopeptide and lipid were allowed to pre-incubate for 10 min at room temperature before the start of
the reaction. Reactions were started by adding 100 mM ATP (ﬁnal concentration) containing 0.1 mCi/mL
of [g32P]-ATP in a total volume of 10 mL. This reactionwas carried out for 10 and 30min, and stopped by
mixing 3 mL of the reaction mixture with 3 mL of 20 mM EDTA. Three microliters of this mixture was
then spotted on a Hybond-C nitrocellulose membrane (GE healthcare). The membrane was washed six
times with a 1 M NaCl/1% phosphoric acid solution. After completion of the last wash, the membrane
was dried for 1 h, followed by a 5–20 min exposure to a phosphor screen (Molecular Dynamics). The
spot intensity on the phosphor screen was imaged using a Typhoon phosphoimager (GE Healthcare)
and quantitated using ImageQuant (GE Healthcare). For experiments determining the phosphopeptide
sensitivity of each isoform, a solution containing the indicated amount of pY along with lipid vesicles
was added as described above to each isoform.HDX measurements
HDX reactions were initiated in HDX buffer (10mMHepes pH-7.4,100mMNaCl, and 2mMTCEP) by
the addition of proteins (3 mM ﬁnal) to either pY solution (15 mM pY ﬁnal) or just pY buffer. This was
allowed to preincubate for at least 15 min followed by the addition of 88% D2O solution (10 mM Hepes
pD-7.4, 50 mM NaCl, and 2 mM TCEP), resulting in a ﬁnal concentration of 78% D2O. “On exchange”
reactions were carried out for 3, 30, 300, and 3000 s at 23 C, followed by addition of a quench buffer,
giving a ﬁnal concentration 0.8% formic acid and 0.5 M Guanidine–HCl. Samples were frozen in liquid
nitrogen, and stored at 80 C until mass analysis.Protein expression and puriﬁcation
Proteins were expressed and puriﬁed as described previously (Burke et al., 2011).Lipid vesicle preparation
Lipid vesicles were prepared as described previously (Burke et al., 2011).Measurement of deuterium incorporation
Samples were rapidly thawed on ice and injected onto a UPLC system immersed in ice as described
previously (Burke et al., 2011). The protein was passed over an immobilized pepsin column (Applied
Biosystems, Poroszyme, 2-3131-00) at 130 mL/min, and onto a particle van-guard trap (Waters) for
3 min. The trap was then eluted onto an Acquity 1.7 mm particle, 100 mm  1 mm C18 UPLC column
(Waters) using a 5–45% gradient (buffer A 0.1% formic acid and buffer B 100% acetonitrile) over 20 min
and injected into an LTQ Orbitrap XL (Thermo Scientiﬁc) acquiring from 350 to 1500 m/z, with an ESI
source operated at a capillary temperature of 225 C, and a spray voltage of 3.5 kV.Protein digestion and peptide identiﬁcation
Peptide identiﬁcation and mass analysis of the peptide centroids was performed as described
previously, using the Mascot search within Proteome Discoverer (Thermo Scientiﬁc) and HD-Examiner
(Sierra Analytics) (Burke et al., 2011). Mascot identiﬁcation thresholds were set at 10 ppm for peptide
tolerance, and 0.3 Da for fragment MS/MS tolerance. All peptides with a mascot score >20 were
analyzed by the HD-Examiner software. All of the peptides were manually validated by searching
a non-deuterated protein sample’s MS scan to test for correctm/z state and to check for the presence of
overlapping peptides. Ambiguous peptides were excluded from the analysis. The list of all p110 and p85
peptides is shown in Fig. S1 for p110 catalytic subunits and Fig. S2 for p85 regulatory subunits.
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Selected peptides were manually examined for deuterium incorporation and accurate identiﬁca-
tion. Results are presented as relative levels of deuteration with no correction for back exchange, since
no fully deuterated protein sample could be obtained. A correction was applied to compensate for
differences in the level of deuterium in the exchange buffer (78%). The average error was 0.2 Da for
corrected data of two replicates. Changes between conditions where the mass difference for a peptide
was greater than 6% and greater than 0.5 Da were considered signiﬁcant. The relative HDX level for
every peptide analyzed for every mutant and time point is shown in Fig. S3, and the differences in HDX
levels between states are shown in Fig. S5. H/D amide exchange in any peptide reported may be due to
any number of amides within the peptide. All samples compared were prepared at the same time, and
acquired on the mass spectrometer in the same session.Fig. 1. PI3K activity assays. A. ATPase activity of all class IA PI3K isoforms in the absence and presence of bis-phosphorylated PDGFR
peptide (pY). This assay is based on displacement of the ADP-Alexa 633 tracer from the ADP2 antibody, dependent on the production of
ADP. B. Lipid kinase activity assay of all class IA PI3K isoforms with varying amounts of pY (from 0.1 to 100 nM). Assays measured 32P-
PIP3 production in the presence of 10 nM enzyme,100 mMATP, and 5% PIP2 lipid vesicles at a concentration of 1mg/ml. The amount of
lipid kinase activity for p110a and p110b in the presence of 0.4 nMpY is shown in the bar graph. C. The effect of nSH2 (K379E) and cSH2
(Y685A) mutations on lipid kinase activity. The lipid kinase activity of full-length recombinant p110/p85 complexes containing the
indicated p85 mutations are shown in the presence and absence of 50 mM pY. D. The pY sensitivity of lipid kinase activity was deter-
mined for all class IA PI3K isoforms in the presence of either the wild type or the Y685A mutant of p85 as described above.
Fig. 2. Basal hydrogen/deuterium exchange differences in the p85 regulatory subunit in the presence of different p110 catalytic
subunits. A. Domain organization of the different p110 catalytic and p85 regulatory subunits. B. Differences in HDX in p85 between
the p110a and p110b complex. In the left panel, a structural model of the nSH2, iSH2, and cSH2 of p85 bound to p110b is shown as
a reference (a composite image generated from PDB ID 2Y3A, 3HHM, 1H9O and 2V1Y). In the right panel, peptides spanning p85a
that showed both greater than 6% and 0.5 Da changes in H/D exchange in between p85 bound to p110a and p110b are colored on the
nSH2, iSH2, and cSH2 and mapped onto a model of p85 bound to p110a (generated from PDB ID 3HHM, 1H9O, and 2V1Y). A
simpliﬁed schematic representation of HDX differences is shown underneath the structural model. C. Differences in HDX in p85
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Basal and pY stimulated activities of p110a, p110b and p110d
Although all class IA PI3Ks associate with p85-related regulatory subunits, the effect of this asso-
ciation varies among the isotypes. While both p110a and p110b are expressed in most cells, several
observations suggest that associationwith phosphorylated RTKs activates p110a, but has less inﬂuence
on p110b (Guillermet-Guibert et al., 2008; Kulkarni et al., 2011). One of the unique aspects of the p110b
is that it is activated by associationwith both Gbg heterodimers and phosphorylated RTKs (Kurosu and
Katada, 2001). Using inhibitors selective for p110b and cells derived from a p110b knockout mouse, it
has been shown that p110b is responsive to GPCR agonists, while it has only a minor role in signaling
downstream of tyrosine kinases (Guillermet-Guibert et al., 2008). It has been proposed that p110b
could provide a mechanism for signaling downstream of GPCRs in non-hemopoietic cells where the
Gbg-responsive isotype p110g is not expressed (Guillermet-Guibert et al., 2008) and that synergy of
response by combined GPCR and RTK activation might be the biological role of the p110b isotype
(Kurosu and Katada, 2001; Kulkarni et al., 2011).
Catalysis in the absence of lipid substrates
In an effort to understand to what extent the differential signaling roles of the class IA PI3Ks
downstream of tyrosine kinases are intrinsic to the enzymes themselves rather than the interactions
that they make with signaling components other than phosphorylated tyrosine-containing peptides
(pY), we examined the mechanisms of pY-mediated activation of all class IA PI3Ks in vitro. As shown in
Fig. 1A, the three class IA isotypes can all act as ATPases, transferring the g-phosphate from ATP to
water in the absence of lipid substrates. Even using this basal activity, it is clear that the three isotypes
differ signiﬁcantly. The p110a/p85a heterodimer has the greatest activity and is about four-fold more
active than p110b/p85a. The p110b/p85a is then about three-fold more active than the p110d/p85a
heterodimer. The greater activity of p110a is consistent with the structures of the enzymes. The C-
terminal region of all PI3Ks is essential for catalysis. It inhibits the basal activity of the enzyme in the
absence of a membrane, and it enhances membrane binding. It has been proposed that this is an
important regulatory element of the PI3Ks (Miller et al., 2010). Structures of p110a show a great deal of
disorder or irregular structure in this region (Huang et al., 2007; Mandelker et al., 2009; Hon et al.,
2012), and this may facilitate entry of water into the active site. In contrast to p110a, the other class
IA enzymes have a partially ordered helix in this region that may be more effective in preventing
catalysis in the absence of membranes (Zhang et al., 2011). Using an excess of a PDGFR-derived bis-
phosphorylated phosphopeptide (pY), the p110a/p85a heterodimer is also activated to a greater extent
than the other isotypes. The ability of the pY to activate ATPase activity is likely due to loss of a contact
between the 339–347 helix of the nSH2 and helix a10 of the C-lobe of the kinase domain. The HDX-MS
results suggest that the 339–347 helix of the nSH2 is more tightly protected in the complex with p110a
compared to the complexes with p110b or p110d (Fig. 2).
RTK peptide stimulation of PI3K activity in the presence of PIP2-containing membranes
Titration with the pY (PDGFR residues 735–767, with pY740 and pY751) shows that the lipid kinase
activity of p110a/p85a complex is stimulated at a lower concentration of the peptide than p110b/p85a
or p110d/p85a heterodimers (Fig. 1B, left panel). Consequently, it is easy to select a condition in which
p110a/p85a is activated, while p110b/p85a shows no signiﬁcant activation (Fig. 1B, right panel). Ourbetween the p110a and p110d complex. In the left panel, structural model of the nSH2, iSH2, and cSH2 of p85 bound to p110d is
shown as a reference (generated from PDB ID 2WXH, 3HHM, 1H9O and 2V1Y). In the right panel, peptides spanning p85a that
showed both greater than 6% and 0.5 Da changes in H/D exchange in between p85 bound to p110a and p110d are colored on the
nSH2, iSH2, and cSH2 and mapped onto a model of p85 bound to p110a. (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of this article.)
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stimulation in cells may be a result of the inherently lower response of the p110b/p85a heterodimer.
We wanted to test whether this lower p110b/p85a sensitivity to RTK stimulation arises from the
inﬂuence of the SH2 domains of the p85 subunit. Structural studies have shown that both the nSH2 and
cSH2 subunits of p85 interact with p110b and p110d (Burke et al., 2011; Zhang et al., 2011) and these
contacts inhibit the enzymes. In contrast, p110a is fully inhibited bya construct that has only the nSH2 and
iSH2 domains (Yu et al., 1998). Although this suggests that the cSH2 has no role in inhibiting p110a,
measurements of activity for deletion variants could have complex and unanticipated consequences on
the structureof the regulatorysubunit and thepotential interactions that it couldmakewith thepYoutside
the SH2domains. Becauseof this,weusedpointmutants in thenSH2andcSH2domains that eliminate the
contact of these domains with the catalytic subunit (Burke et al., 2011; Zhang et al., 2011). The K379E
mutation in the nSH2 eliminates the interaction between the helical domain of the catalytic subunit and
the nSH2 by breaking a salt bridge between E545 and K379. In addition to stimulating PI3K in vitro (Miled
et al., 2007; Burke et al., 2011; Zhang et al., 2011), this mutation is oncogenic in cells (Sun et al., 2010;
Hofmannand Jücker, 2012). TheY685Amutation replacesa tyrosine that isessential forcontactof thecSH2
with the C-lobes of the p110b and p110d kinase domains, thereby eliminating the inhibitory capability of
the cSH2,without affecting its ability to bindpY (Burke et al., 2011; Zhang et al., 2011). As shown in Fig.1C,
the K379E mutation increases the basal activity of all three isotypes. In contrast, the Y685A mutation
increases the basal activity of only p110b andp110d. TheK379Emutation renders p110a fully active so that
no further activation is achieved by addition of pY. Either K379E or Y685A mutants can be further stim-
ulated by pY for both p110b and p110d. The double mutant K379E/Y685A fully activates all isotypes.
Both HDX-MS and activity assays indicate that the cSH2 makes an inhibitory contact with the
catalytic subunit only for p110b and p110d but not for p110a. The lack of an inhibitory effect of p110a is
consistent with a previous report (Yu et al., 1998). However, the same report also showed that bis-
phosphorylated IRS-1 activation of p110a/p85 was diminished when the cSH2 was mutated to
prevent pY binding. It was proposed that the presence of residues 1–322 (containing the SH3 and BH
domains) facilitates a conformational change in p85 such that pY binding to the cSH2 facilitates release
of nSH2-mediated inhibition. Our results demonstrating that the Y685A mutation prevents the
inhibitory contact of the cSH2 domain with p110b and p110d, with no inﬂuence on p110a, do not
exclude such amechanism, because the Y685Amutation does not affect phosphopeptide binding to the
cSH2 (Zhang et al., 2011).
To test whether the lack of the cSH2 inhibitory contact was responsible for the higher pY sensitivity
of p110a (Fig. 1B), we examined the pY sensitivity for all three class IA p110 isoforms in the presence of
either the wild type or Y685A p85 constructs. We found that the presence of the Y685A mutation had
no effect on the pY sensitivity of any isoforms (Fig. 1D). Therefore the mechanism of enhanced
sensitivity of p110a relative to the other isoforms remains unknown.
H/D exchange mass spectrometry of the basal states of class IA enzymes in complexes with p85a
We have used HDX-MS to investigate the dynamic structural consequences of the differences in
interactions between the p85 regulatory subunit and the three class IA enzymes in the basally inhibited
state (Fig. 2). We were able to identify a number of peptic peptides for each of the class IA catalytic
isoforms (Fig. S1) and the p85 regulatory subunit (Fig. S2). For all peptides, we quantiﬁed the relative
deuteration level at four timepoints (3, 30, 300, and 3000 s) and the full H/D exchange data is shown in
Fig. S3. Experiments were carried both in the presence and absence of pY. The global deuteration level
of p110a, p110b and p110d at three timepoints are shown in Fig. S4. We were able to determine the
difference in HDX levels for all three p110/p85 heterodimers in the presence of pY, as well as the
difference in the p85 subunits in the presence of different catalytic isoforms (Fig. S5).
Comparison of H/D exchange in the cSH2 among class IA heterodimers
Comparing the HDX levels of the p85 subunit in the presence of various catalytic subunits enabled
us to uncover differences in how the p110 subunits interact with p85. We ﬁnd that the main difference
between the isoforms is that the cSH2 has much higher H/D exchange rates (i.e., is much more
exposed) in the presence of the p110a catalytic subunit compared to p110b and p110d (Fig. 2A,B). This is
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ments showing no inhibitory inﬂuence of the cSH2.
Comparison of H/D exchange in the nSH2 among class IA heterodimers
In contrast to the cSH2, interaction with p110a results in decreased HDX in the nSH2 and iSH2
compared with either p110b or p110d (Fig. 2). The one area in the nSH2 that shows decreased HDX in
p110a compared to p110b and p110d is the helix A (residues 339–347), which is in contact with the C-
terminal lobe of the kinase domain in the crystal structure of p110a bound to the niSH2 fragment of
p85 (Mandelker et al., 2009; Vadas et al., 2011). This may explain why the nSH2 more strongly inhibits
the p110a subunit compared to p110b, and p110d (Fig.1C). There is also a large increase in HDX in the C-
terminus of the nSH2 (414–420) in p110d compared to both p110a and p110b. Although there is no
crystal structure of the p110b or p110d interacting with the nSH2, the HDX-MS suggests that there are
conformational differences with respect to p110a that result in more protection of the nSH2, likely due
to it making more extensive contacts in the p110a/p85 complex.
H/D exchange mass spectrometry of the pY activated states of the class IA PI3Ks
H/D exchange comparison of the helical domains of class IA complexes
All three class IA PI3Ks showan increase in exchange in the helical domain of the p110 subunit in the
presence of 15 mMbis-phosphorylated PDGFR-derived peptide (Fig. 3). This exposure is consistent with
the pY causing release of the inhibitory contact of the nSH2 with the helical domain. In addition, pY
binding exposes a region near the N-terminal end of the ﬁrst long helix in the coiled-coil iSH2 domain.
This exposure is likely the result of an increase in dynamics of the nSH2/iSH2 linker upon freeing the
nSH2 domain from contact with the catalytic subunit. For p110b and p110d, there is also an increase in
exposure of the C-terminal end of the second helix of the iSH2, and this is likely due to freeing the cSH2.
No increase in exposure of this helix for p110a is consistent with the cSH2 being already free in the
basal state for the p110a/p85 complex.
H/D exchange comparison of the C2/iSH2 interfaces of class IA complexes
There is an inhibitory interaction between the C2 domain and the second helix of the iSH2, and
mutants that disrupt this interaction, such as mutants of D560 and N564 in the iSH2 domain are
oncogenic for all class IA PI3Ks (Zhao and Vogt, 2008; Jaiswal et al., 2009). Mutations of residues at this
interface for p110a/p85 result in an increase in HDX in the second helix of the iSH2 as well as for the
loop in the C2 domain that contains N345 (Burke et al., 2012). The p110b/p85 complex is unique among
the class IA enzymes in that pY binding causes a larger increase in HDX across most of the iSH2
compared to other isozymes (Fig. 3B). Interestingly, we have found that many of the HDX changes we
see in the iSH2 for p110b upon pY binding are seen uponmembrane binding by the pY-activated p110a,
and p110d (Burke et al., 2011, 2012). These results suggest that all three class IA enzymes undergo
similar conformational changes upon full activation, but that these conformational changes are elicited
by different stimuli. This implies that the p110b/p85 inhibitory contacts at the C2/iSH2 interface are
weaker in the basal state and are consequently disrupted by simple pY binding, whereas p110a, and
p110d require in addition subsequent membrane binding to achieve the same state. This view of the
natural activation process gives some insight into the mechanism of up-regulation of PI3Ks in tumors.
Oncogenic mutations in p110a mimic the dynamic changes induced by pY binding and by membrane
binding in the WT enzyme (Burke et al., 2012).
It has been suggested that p110b represents an activated PI3K relative to p110a based on the
observation that p110a undergoes numerous spontaneous gain-of-function mutations in human
cancers (Brown and Auger, 2011; Vogt, 2011), and transfection of the wild-type p110a is not oncogenic,
whereas transfection of wild-type p110b and p110d is (Zhao et al., 2005; Kang et al., 2006; Huang et al.,
2008). In p110a, residue N345 interacts with D560 and N564, and mutation of residues involved in this
interaction leads to increased PI3K signaling and oncogenesis (Huang et al., 2008; Jaiswal et al., 2009;
Zhang et al., 2011). It was proposed that this inhibitory cSH2/iSH2 interaction is disrupted in the wild-
type p110b relative to p110a due to a sequence difference in p110b relative to p110a at human p110b
residue K342 (Dbouk et al., 2010). However, other studies showed that the p85 D564N mutation is
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the mouse p110b/p85b complex shows that D560 and N564 are nearest to S467 and S468 in p110b and
that the residue that was proposed before the structure was reported to be equivalent to K342 in
human p110b is actually not at the p110b/p85b interface (Zhang et al., 2011). Our HDX data for p110b
indicate that the region of the iSH2 in contact with the C2 is more exposed in p110b compared to either
p110a or p110d (Fig. 2B), and that the addition of pY is sufﬁcient to further expose this region, which
does not occur for p110a or p110d. This indicates that the C2/iSH2 contacts exist in p110b, but they are
muchmore dynamic for p110b, which is consistent with the proposal that p110b is less inhibited by the
iSH2 than p110a (Dbouk et al., 2010) (Fig. 4).
H/D exchange comparison of the kinase domains among the class IA isozymes
Only p110b and p110d show an exposure in the C-lobe of the kinase domain in response to pY
binding (Fig. 2). Concomitant with exposure of the kinase domain C-lobe is exposure of a peptide in the
cSH2 that corresponds to the site that contacts the C-lobe in the crystal structure of the p110b/p85b
complex (Zhang et al., 2011). This is the peptide containing Y685 whose mutation leads to p110b and
p110d activation (Fig. 1C). In contrast, the p110a subunit shows no signiﬁcant changes in exposure of
the kinase domain and no exposure of the cSH2 in response to pY binding. These HDX-MS results are
consistent with the activity assays for the mutant p85 subunits that show that the cSH2 domain does
not inhibit p110a (Fig.1C). There is no exposure of the nSH2 for any of the class IA complexes, and this is
likely because the same region that would become exposed by releasing from the p110 subunit
becomes buried in the interaction with the pY. Recent work on p110a containing the E545K mutation,
which mimics the release of the nSH2 caused by pY binding showed exposure of the nSH2 conﬁrming
this hypothesis (Burke et al., 2012). This contrasts with the cSH2 domain because the site of contact
with the p110 subunit and the pY binding sites do not coincide (They are on opposite sides of the cSH2
domain). Only peptides long enough to reach from the pY binding site to the surface of the p110 subunit
are capable of displacing the cSH2 domain and thereby activating p110b/p85 (Zhang et al., 2011).
H/D exchange in the BH domain
For the three class IA PI3Ks, there is an increase in exposure of the BH domain on pY binding (Fig. 3),
suggesting that there may be a contact between the BH domain and another region in the p85 subunit
or the p110 subunit that is released on pY binding. The peptide in the BH domain that becomes exposed
(residues 149–158) corresponds to a region that is close to the crystallographic dimer interface in the
BH domain structure (Musacchio et al., 1996), although the BH domain is not a dimer when expressed
in isolation. It may be that the crystal dimer mimics a contact that the domain makes in the context of
the full PI3K.
Interpretation of HDX-MS results in terms of structural dynamics
Although the HDX-MS results can be readily used to estimate the amplitudes of structural ﬂuctu-
ation upon pY binding, there is no information about the direction of the movement. Normal mode
analysis of protein structures can be used to computationally estimate conformational ﬂuctuation. The
elastic network model of normal mode analysis (Tama and Sanejouand, 2001) uses an extremely
simpliﬁed potential energy function so that it is computationally tractable. The analysis generates an
estimation of the direction of conformational ﬂuctuation that in many cases agrees with experimen-
tally observed changes in structure (Tama and Sanejouand, 2001).Fig. 3. HDX differences in the p110 catalytic and p85 regulatory subunits in the presence of pY. A. The structural model of SH2
binding to the p110 catalytic subunit based on the crystal structures of p110a bound to the niSH2 fragment of p85, and p110b bound
to the icSH2 fragment of p85. The p85 is colored green and the p110 subunit is gray. B. Peptides that showed HDX differences in
p110a/p85a in the presence of 15 mM pY are mapped and colored onto a model of the p110a/p85a complex. A simpliﬁed schematic
representation to the right of the structural model helps orient the location of HDX differences. C. Peptides that showed HDX
differences in p110b/p85a in the presence of 15 mM pYare mapped and colored onto a model of the p110b/p85a complex. D. Peptides
that showed HDX differences in p110d/p85a in the presence of 15 mM pY are mapped and colored onto a model of the p110d/p85a
complex. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 4. Differential regulation of the class IA PI3Ks by p85. Schematic representation of inhibitory interactions between the p110 and
p85 subunits. The p110a subunit has only two inhibitory ‘brakes’ on kinase activity, one from the nSH2 and one from the iSH2. In
p110b there are three brakes on lipid kinase activity, due to inhibitory contacts with the nSH2, iSH2, and cSH2, however our HDX
results show that the nSH2 and iSH2 ‘brakes’ are slightly disrupted in the basal state compared to p110a. In p110d there are also three
‘brakes’ on activity from the nSH2, iSH2, and cSH2, however in this case only the nSH2 ‘brake’ is partially disrupted in the basal state,
and the iSH2 ‘brake’ remains fully inhibitory.
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In Movie 1, we illustrate the lowest frequency normal modes for p110a and for p110b. For the
purpose of these calculations, we have used only the p110/iSH2 complex, since the iSH2 domain is the
only domain of p85 that is in common between the p110a and p110b crystal structures. The extremely
simpliﬁed potential function used for these calculations means that the normal mode is dominated by
the shape of the complex (Tama and Sanejouand, 2001). This analysis suggests a ﬂuctuation of the ABD/
iSH2 relative to the rest of the p110 subunit. We have previously observed an exposure of the ABD-RBD
linker in p110a upon membrane binding that we proposed was a consequence of the ABD moving
relative to the rest of the catalytic subunit (Burke et al., 2012). This is consistent with the exposure in
the backbone amides of the iSH2 domains that occurs in p110a and p110d uponmembrane binding and
in p110b upon pY binding as measured by HDX-MS. In the p110a/p85 heterodimer, there are many
mutations of the p110 and p85 subunits that are associated with cancers, and these up-regulating
mutations facilitate the closed-to-open transition that makes these mutant enzymes have a greater
afﬁnity for lipid membranes (Burke et al., 2011, 2012; Hon et al., 2012). As illustrated in Movie 1, many
of the regions where exposure of the p110/p85 complex elicited either by pYandmembrane binding for
p110a or by pY binding alone for p110b correspond to regions containing oncogenic mutations in
p110a. Equivalent oncogenic mutations of p110b are not observed in human cancers, and our HDX-MS
results show that p110b in many ways mimics the dynamics that we see in oncogenic mutations of
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oncogenic mutants seen in p110a (Brown and Auger, 2011). The normalmode analysis suggests that the
large-scale conformational motions most easily accommodated by the shape of the complex broadly
agree with the conformational changes elicited by the perturbing inﬂuences of pY binding, membrane
binding and oncogenic mutations.
Conclusions
The observation that p110a is involved in signaling downstream of receptor tyrosine kinases in
preference to p110bmay reﬂect the enhanced sensitivity to pYactivation thatwe see in vitro. Thiswould
also be consistent with a model proposed for prostate epithelial cells in which p110a activity is stimu-
lated by insulinwhereas p110b provides a baseline level of PIP3 production (Knight et al., 2006; Jia et al.,
2008). The role of p110b may be particularly important in a cellular context where it is synergistically
activated byGbg heterodimers downstream of G-protein coupled receptors. Structural and biochemical
methods, including X-ray crystallography and HDX-MS, suggest that class IA PI3K lipid kinase activity is
differentially regulated by ‘brakes’ provided by the nSH2, iSH2, and cSH2 of the p85 regulatory subunit
(Fig. 4). Our results also suggest that there are stereotypical conformational changes within the class I
PI3Ks that accompany activation by RTK pY peptides and membrane binding and that these confor-
mational changes can be induced byoncogenicmutations. Because these activating inﬂuences converge
on membrane interaction, the HDX-MS results could act as a roadmap to design inhibitors that would
work by preventing the closed-to-open transition that occurs upon activation and membrane binding.
Given the wealth of structural information available for the class I PI3Ks, approaches such as tethering
(Hyde et al., 2003; Raimundo et al., 2004; Sadowsky et al., 2011) could be taken to develop small
molecule inhibitors that would lock the enzyme in the closed state.
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